The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | Replacing autoSCT with immunotherapies: pros and cons
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, shares some of the main points from a debate held at COMy 2022 which focused on immunotherapies replacing autologous stem cell transplant (autoSCT) in myeloma. Dr Richardson first highlights the benefits of autoSCT, including improved progression-free survival (PFS) and overall survival (OS), and further explains the importance of melphalan in myeloma treatment. Following this, Dr Richardson comments on the future of myeloma therapy and whether treatment approaches can be improved with novel immunotherapies including CAR-T and antibodies, as well as the importance of using measurable residual disease (MRD) as a guide. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
